RxSight
RXST
115 hedge funds and large institutions have $637M invested in RxSight in 2023 Q2 according to their latest regulatory filings, with 48 funds opening new positions, 45 increasing their positions, 13 reducing their positions, and 7 closing their positions.
1,345% more call options, than puts
Call options by funds: $1.42M | Put options by funds: $98K
586% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 7
246% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 13
141% more capital invested
Capital invested by funds: $264M → $637M (+$373M)
55% more funds holding
Funds holding: 74 → 115 (+41)
18.17% more ownership
Funds ownership: 46.92% → 65.09% (+18%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$32.3M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$24.3M |
| 3 |
Millennium Management
New York
|
+$12.2M |
| 4 |
ACM
Atika Capital Management
New York
|
+$11.4M |
| 5 |
BlackRock
New York
|
+$8.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$20.1M |
| 2 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$12.6M |
| 3 |
BAM
Belpointe Asset Management
Reno,
Nevada
|
-$1.76M |
| 4 |
BM
Bridger Management
New York
|
-$1.65M |
| 5 |
MF
Magnetar Financial
Evanston,
Illinois
|
-$1.47M |
RXST Hedge Fund Activity: Q2 2023 in Review
115 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in RxSight (RXST) for Q2 2023, worth a combined $637M — up 141% from $264M a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new RXST positions and 7 closed out — a net gain of 41 holders — while 45 added to existing stakes and 13 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $32.3M. The largest seller was OrbiMed, exiting entirely with an estimated $20.1M sold.
- 115 institutional investors held RxSight (RXST) as of Q2 2023, up from 74 in Q1 2023.
- Funds reported $637M of RxSight stock for Q2 2023, up 141% quarter-over-quarter.
- 48 funds opened new RxSight positions in Q2 2023 and 7 closed out, a net change of +41 holders.
- The largest RxSight buyer in Q2 2023 was Morgan Stanley, an estimated $32.3M added.
- The largest RxSight seller in Q2 2023 was OrbiMed, an estimated $20.1M sold.
Based on aggregated 13F filings for Q2 2023.